Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000 NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental...

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental...

Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and commercialization of novel...